Leerink Partnrs Weighs in on NTLA Q1 Earnings
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($1.39) per share for the quarter. The consensus […]
Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($1.39) per share for the quarter. The consensus […]
